Wave Life Sciences, Inc. (WVE) analyst actions
Rating and price-target actions on WVE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the WVE overview →
5 measured WVE analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity | Press release | -0.12% | -7.49% | |
| Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases | Press release | +1.32% | -1.81% | |
| Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity | Press release | +0.45% | -3.50% | |
| Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy | Press release | +0.66% | -3.71% | |
| Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency | Press release | +2.60% | +3.69% |
Keep exploring
More WVE: earnings → · SEC filings → · WVE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Verona Pharma plc - American Depositary Shares (VRNA) | 325 | -0.03% | 39% |
| Bionano Genomics, Inc. (BNGO) | 321 | -0.94% | 31% |
| Pulse Biosciences, Inc (PLSE) | 320 | +0.18% | 55% |
| Voyager Therapeutics, Inc. (VYGR) | 320 | -0.12% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.